301393 昊帆生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)2.9774.9625.9847.34730.268
总资产报酬率 ROA (%)2.5574.5825.7826.85724.292
投入资产回报率 ROIC (%)2.7564.8415.9477.24128.561

边际利润分析
销售毛利率 (%)35.41234.82740.28238.55343.258
营业利润率 (%)21.53223.95234.49928.95233.353
息税前利润/营业总收入 (%)22.25220.09026.96021.90732.397
净利润/营业总收入 (%)18.29818.40529.66625.45728.912

收益指标分析
经营活动净收益/利润总额(%)86.54090.70085.06397.99298.457
价值变动净收益/利润总额(%)13.29718.94710.7261.5410.265
营业外收支净额/利润总额(%)-0.245-11.592-0.812-0.068-0.191

偿债能力分析
流动比率 (X)4.9067.07527.32129.8323.226
速动比率 (X)4.4326.40025.68128.0852.188
资产负债率 (%)16.46111.1223.4623.28319.627
带息债务/全部投入资本 (%)9.8513.4010.2370.1583.600
股东权益/带息债务 (%)909.1652,819.99141,891.25762,960.8562,631.580
股东权益/负债合计 (%)506.424796.9372,788.2642,946.103409.499
利息保障倍数 (X)28.776-14.618-3.713-3.119-36.296

营运能力分析
应收账款周转天数 (天)89.17975.19161.17451.63047.038
存货周转天数 (天)120.109127.435154.552172.124136.362